207 related articles for article (PubMed ID: 23217055)
1. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.
Li Y; Figler RA; Kolling G; Bracken TC; Rieger J; Stevenson RW; Linden J; Guerrant RL; Warren CA
BMC Infect Dis; 2012 Dec; 12():342. PubMed ID: 23217055
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
[TBL] [Abstract][Full Text] [Related]
4. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
5. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
Tanaka Y; Tashiro S; Ikegami S; Enoki Y; Taguchi K; Matsumoto K
Anaerobe; 2023 Dec; 84():102789. PubMed ID: 37879532
[TBL] [Abstract][Full Text] [Related]
6. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
7. Mouse relapse model of Clostridium difficile infection.
Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
9. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.
Buffie CG; Jarchum I; Equinda M; Lipuma L; Gobourne A; Viale A; Ubeda C; Xavier J; Pamer EG
Infect Immun; 2012 Jan; 80(1):62-73. PubMed ID: 22006564
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Chicken IgY Specific to
Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
[No Abstract] [Full Text] [Related]
13. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
14. MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets.
Steele J; Zhang Q; Beamer G; Butler M; Bowlin T; Tzipori S
Antimicrob Agents Chemother; 2013 Aug; 57(8):4039-41. PubMed ID: 23689716
[TBL] [Abstract][Full Text] [Related]
15. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model.
Budi ND; Godfrey JJ; Safdar N; Shukla SK; Rose WE
J Infect Dis; 2023 Mar; 227(5):622-630. PubMed ID: 35904942
[TBL] [Abstract][Full Text] [Related]
17. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
[TBL] [Abstract][Full Text] [Related]
18. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
19. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation.
Rork TH; Wallace KL; Kennedy DP; Marshall MA; Lankford AR; Linden J
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H1825-33. PubMed ID: 18757481
[TBL] [Abstract][Full Text] [Related]
20. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]